What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis

Published:2017-08-10 Issue:59 Volume:8 Page:100508-100523
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Xie Hui¹²,Yu Haipeng¹,Tian Shengtao²,Yang Xueling¹,Wang Ximing²,Yang Zhao²,Wang Huaming²,Guo Zhi¹

Affiliation:

1. Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300070, China

2. Department of Interventional Therapy, 302 Hospital of People's Liberation Army, Beijing 100039, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel nanoparticle CS-C60-Fe3O4 magnetically induces tissue-specific aggregation and enhances thermal ablation of hepatocellular carcinoma;Cancer Nanotechnology;2024-01-23

2. Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials;Frontiers in Oncology;2023-06-08

3. Transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma: Long-term results of RTF3 regimen;Cancer/Radiothérapie;2023-06

4. Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma;Strahlentherapie und Onkologie;2022-11-28

5. Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC;Frontiers in Oncology;2022-10-28